Forskning ved Københavns Universitet - Københavns Universitet

Forside

Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. / Persson, Frederik; Lewis, Julia B; Lewis, Edmund J; Rossing, Peter; Hollenberg, Norman K; Parving, Hans-Henrik; AVOID Study Investigators.

I: Diabetes Care, Bind 33, Nr. 11, 01.11.2010, s. 2304-9.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Persson, F, Lewis, JB, Lewis, EJ, Rossing, P, Hollenberg, NK, Parving, H-H & AVOID Study Investigators 2010, 'Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy', Diabetes Care, bind 33, nr. 11, s. 2304-9. https://doi.org/10.2337/dc10-0833

APA

Persson, F., Lewis, J. B., Lewis, E. J., Rossing, P., Hollenberg, N. K., Parving, H-H., & AVOID Study Investigators (2010). Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care, 33(11), 2304-9. https://doi.org/10.2337/dc10-0833

Vancouver

Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving H-H o.a. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care. 2010 nov 1;33(11):2304-9. https://doi.org/10.2337/dc10-0833

Author

Persson, Frederik ; Lewis, Julia B ; Lewis, Edmund J ; Rossing, Peter ; Hollenberg, Norman K ; Parving, Hans-Henrik ; AVOID Study Investigators. / Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. I: Diabetes Care. 2010 ; Bind 33, Nr. 11. s. 2304-9.

Bibtex

@article{1d8d53a4fea34acb9edee1497d31529a,
title = "Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy",
abstract = "Proteinuric diabetic patients with reduced glomerular filtration rate (GFR) are at high risk of renal and cardiovascular disease progression and treatment-related adverse events. This post hoc analysis assessed the efficacy and safety of aliskiren added to the maximal recommended dose of losartan according to baseline estimated GFR (eGFR) (stage 1-3 chronic kidney disease [CKD]).",
author = "Frederik Persson and Lewis, {Julia B} and Lewis, {Edmund J} and Peter Rossing and Hollenberg, {Norman K} and Hans-Henrik Parving and Hans-Henrik Parving",
year = "2010",
month = "11",
day = "1",
doi = "http://dx.doi.org/10.2337/dc10-0833",
language = "English",
volume = "33",
pages = "2304--9",
journal = "Diabetes Care",
issn = "0149-5992",
publisher = "American Diabetes Association",
number = "11",

}

RIS

TY - JOUR

T1 - Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy

AU - Persson, Frederik

AU - Lewis, Julia B

AU - Lewis, Edmund J

AU - Rossing, Peter

AU - Hollenberg, Norman K

AU - Parving, Hans-Henrik

AU - AVOID Study Investigators

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Proteinuric diabetic patients with reduced glomerular filtration rate (GFR) are at high risk of renal and cardiovascular disease progression and treatment-related adverse events. This post hoc analysis assessed the efficacy and safety of aliskiren added to the maximal recommended dose of losartan according to baseline estimated GFR (eGFR) (stage 1-3 chronic kidney disease [CKD]).

AB - Proteinuric diabetic patients with reduced glomerular filtration rate (GFR) are at high risk of renal and cardiovascular disease progression and treatment-related adverse events. This post hoc analysis assessed the efficacy and safety of aliskiren added to the maximal recommended dose of losartan according to baseline estimated GFR (eGFR) (stage 1-3 chronic kidney disease [CKD]).

U2 - http://dx.doi.org/10.2337/dc10-0833

DO - http://dx.doi.org/10.2337/dc10-0833

M3 - Journal article

VL - 33

SP - 2304

EP - 2309

JO - Diabetes Care

JF - Diabetes Care

SN - 0149-5992

IS - 11

ER -

ID: 34163192